(SCNX) Scienture Holdings - Ratings and Ratios
Pharmaceutical, Generic, Branded, Injectables, Oral
SCNX EPS (Earnings per Share)
SCNX Revenue
Description: SCNX Scienture Holdings
Scienture Holdings, Inc. (NASDAQ:SCNX) is a pharmaceutical company that focuses on developing and commercializing treatments for central nervous system and cardiovascular diseases. The company operates through two segments: Integra, which handles wholesale and sales of licensed pharmaceutical brands, generics, and non-drug products, and Scienture, which is responsible for researching and developing branded pharmaceutical products.
The companys pipeline includes several promising candidates, such as SCN-102, an oral liquid formulation of losartan potassium for treating hypertension and diabetic nephropathy, currently in Phase 1. Other notable candidates include SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen, SCN-106, a thrombolytic agent, and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical pain management.
Analyzing the technical data, the stocks last price is $0.90, with a 20-day SMA of $0.93 and a 50-day SMA of $1.15, indicating a potential downtrend. The 200-day SMA is $4.97, suggesting a significant long-term decline. The ATR is $0.08, representing a 9.26% volatility. The stock has traded between $0.78 and $20.92 over the past 52 weeks, indicating high volatility.
From a fundamental perspective, Scienture Holdings has a market capitalization of $27.09M USD, with a forward P/E ratio of 21.83, suggesting potential for growth. The companys RoE is 19.13%, indicating relatively strong profitability.
Combining technical and fundamental analysis, a forecast for SCNX can be made. Given the current downtrend and high volatility, a potential trading range could be between $0.80 and $1.20 in the short term. However, if the companys pipeline candidates, particularly SCN-102, show positive results in Phase 1, the stock could experience a significant surge. Long-term investors may consider accumulating positions around the current price, targeting a potential price of $5-7 if the companys products gain FDA approval and achieve commercial success. A stop-loss around $0.70-$0.80 is recommended to limit potential losses.
SCNX Stock Overview
| Market Cap in USD | 27m |
| Sector | Healthcare |
| Industry | Pharmaceutical Retailers |
| GiC Sub-Industry | Health Care Technology |
| IPO / Inception | 2010-04-27 |
SCNX Stock Ratings
| Growth Rating | -91.5 |
| Fundamental | 25.0% |
| Dividend Rating | 1.0 |
| Rel. Strength | -63.4 |
| Analysts | - |
| Fair Price Momentum | 1.25 USD |
| Fair Price DCF | - |
SCNX Dividends
Currently no dividends paidSCNX Growth Ratios
| Growth Correlation 3m | 90.1% |
| Growth Correlation 12m | -81.8% |
| Growth Correlation 5y | -83.6% |
| CAGR 5y | -48.32% |
| CAGR/Max DD 5y | -0.49 |
| Sharpe Ratio 12m | -1.63 |
| Alpha | -132.24 |
| Beta | 3.406 |
| Volatility | 165.54% |
| Current Volume | 240.9k |
| Average Volume 20d | 159.5k |
| Stop Loss | 1.9 (-9.1%) |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-15.2m TTM) > 0 and > 6% of Revenue (6% = 8814 TTM) |
| FCFTA -0.13 (>2.0%) and ΔFCFTA -0.12pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 247.5% (prev 356.0%; Δ -108.5pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.07 (>3.0%) and CFO -7.03m > Net Income -15.2m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 1.05 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (9.43m) change vs 12m ago 296.4% (target <= -2.0% for YES) |
| Gross Margin 4.55% (prev -68.84%; Δ 73.39pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.24% (prev 18.59%; Δ -18.35pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -6.97 (EBITDA TTM -13.2m / Interest Expense TTM 1.91m) >= 6 (WARN >= 3) |
Altman Z'' -4.47
| (A) 0.00 = (Total Current Assets 7.83m - Total Current Liabilities 7.46m) / Total Assets 106.4m |
| (B) -0.40 = Retained Earnings (Balance) -42.1m / Total Assets 106.4m |
| (C) -0.22 = EBIT TTM -13.3m / Avg Total Assets 61.5m |
| (D) -1.67 = Book Value of Equity -42.1m / Total Liabilities 25.2m |
| Total Rating: -4.47 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 25.00
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -49.69% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.05 = 2.50 |
| 5. Debt/Ebitda -0.28 = -2.50 |
| 6. ROIC - WACC -38.03% = -12.50 |
| 7. RoE -23.71% = -2.50 |
| 8. Revenue Trend data missing |
| 9. Rev. CAGR -85.37% = -2.50 |
| 10. EPS Trend data missing |
| 11. EPS CAGR 45.31% = 2.50 |
What is the price of SCNX shares?
As of August 13, 2025, the stock is trading at USD 2.09 with a total of 240,935 shares traded.Over the past week, the price has changed by +0.97%, over one month by +26.67%, over three months by +122.36% and over the past year by -67.34%.
Is Scienture Holdings a good stock to buy?
No, based on ValueRay´s Fundamental Analyses, Scienture Holdings (NASDAQ:SCNX) is currently (August 2025) a stock to sell. It has a ValueRay Fundamental Rating of 25.00 and therefor a negative outlook according to the companies health.Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SCNX is around 1.25 USD . This means that SCNX is currently overvalued and has a potential downside of -40.19%.
Is SCNX a buy, sell or hold?
Scienture Holdings has no consensus analysts rating.What are the forecasts/targets for the SCNX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 1.5 | -28.2% |
Last update: 2025-08-05 05:12
SCNX Fundamental Data Overview
CCE Cash And Equivalents = 2.05m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 21.8341
P/B = 0.3182
Beta = None
Revenue TTM = 146.9k USD
EBIT TTM = -13.3m USD
EBITDA TTM = -13.2m USD
Long Term Debt = 1.09m USD (from longTermDebt, last quarter)
Short Term Debt = 2.58m USD (from shortTermDebt, last quarter)
Debt = 3.67m USD (Calculated: Short Term 2.58m + Long Term 1.09m)
Net Debt = 1.76m USD (from netDebt column, last quarter)
Enterprise Value = 28.7m USD (27.1m + Debt 3.67m - CCE 2.05m)
Interest Coverage Ratio = -6.97 (Ebit TTM -13.3m / Interest Expense TTM 1.91m)
FCF Yield = -49.69% (FCF TTM -14.3m / Enterprise Value 28.7m)
FCF Margin = -9711 % (FCF TTM -14.3m / Revenue TTM 146.9k)
Net Margin = -10.4k% (Net Income TTM -15.2m / Revenue TTM 146.9k)
Gross Margin = 4.55% ((Revenue TTM 146.9k - Cost of Revenue TTM 140.2k) / Revenue TTM)
Tobins Q-Ratio = -0.68 (set to none) (Enterprise Value 28.7m / Book Value Of Equity -42.1m)
Interest Expense / Debt = 18.26% (Interest Expense 670.8k / Debt 3.67m)
Taxrate = 21.0% (US default)
NOPAT = -13.3m (EBIT -13.3m, no tax applied on loss)
Current Ratio = 1.05 (Total Current Assets 7.83m / Total Current Liabilities 7.46m)
Debt / Equity = 0.05 (Debt 3.67m / last Quarter total Stockholder Equity 81.2m)
Debt / EBITDA = -0.28 (Net Debt 1.76m / EBITDA -13.2m)
Debt / FCF = -0.26 (Debt 3.67m / FCF TTM -14.3m)
Total Stockholder Equity = 64.3m (last 4 quarters mean)
RoA = -14.33% (Net Income -15.2m, Total Assets 106.4m )
RoE = -23.71% (Net Income TTM -15.2m / Total Stockholder Equity 64.3m)
RoCE = -20.34% (Ebit -13.3m / (Equity 64.3m + L.T.Debt 1.09m))
RoIC = -19.96% (NOPAT -13.3m / Invested Capital 66.6m)
WACC = 18.08% (E(27.1m)/V(30.8m) * Re(18.57%)) + (D(3.67m)/V(30.8m) * Rd(18.26%) * (1-Tc(0.21)))
Shares Correlation 5-Years: 100.0 | Cagr: 76.92%
Discount Rate = 18.57% (= CAPM, Blume Beta Adj.) -> capped to 17.95% (dynamic)
Fair Price DCF = unknown (Cash Flow -14.3m)
Revenue Correlation: N/A | Revenue CAGR: -85.37%
Revenue Growth Correlation: -28.40%
EPS Correlation: N/A | EPS CAGR: 45.31%
EPS Growth Correlation: -12.59%
Additional Sources for SCNX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle